The downregulation of HSP70, achieved through gene editing of surviving, enhances the therapeutic efficacy of GNR-mediated PTT, showcasing the potential of this versatile nanoplatform in bimodal synergistic cancer treatment [182]. The gene discussed is HSPA1A; the disease is cancer.